Yoshizato et al. compared the prognosis of TP53-mutant MDS in combination with complex karyotypes to patients with TP53 mutations but without complex karyotypes, and showed that the TP53 mutation-alone patients had a significantly better OS compared to those with both TP53 mutation and complex karyotypes [72]. This evidence concerns the gene TP53 and myelodysplastic syndrome.